Avicena Group, Inc. has announced that it has filed a composition of matter patent application with the United States Patent and Trademark Office to cover potential treatments for Parkinson's disease, a progressive neurodegenerative disease.
This composition of matter patent broadly covers pharmaceutical formulations based on creatine derivatives alone or in combination with an anti-inflammatory compound for the treatment of Parkinson's. The Company believes that this patent will further strengthen its intellectual property portfolio in Parkinson's, building upon existing use patents previously issued to Avicena with claims in neurology (US Patents 6,196,115 B1 and 6,706,764 B2). Specifically, this patent will provide additional IP protection for its current Parkinson's disease drug candidate, PD-02, and future generation drug candidates formulated to treat Parkinson's.
"This patent application is indicative of our efforts to create shareholder value by building our IP estate to provide additional protection for our cellular energy franchise and our Parkinson's disease drug candidates", stated Belinda Tsao-Nivaggioli, Ph.D., CEO of Avicena. "As previously announced, the National Institutes of Health (NIH) initiated a Phase III trial evaluating our PD-02 compound to verify its ability to slow the progression of Parkinson's disease. As we enter later stage clinical trials and approach potential marketing approvals and commercialization, the strength of our IP becomes increasingly important."